NovaBay Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2018 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
NovaBay Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2018 to Q3 2024.
  • NovaBay Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 465 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 465 +484 Sep 30, 2024
Q2 2024 215 +237 Jun 30, 2024
Q1 2024 127 +149 Mar 31, 2024
Q4 2023 89.6 +114 Dec 31, 2023
Q3 2023 -18.7 -80.1 -131% Sep 30, 2023
Q2 2023 -21.9 -77.6 -139% Jun 30, 2023
Q1 2023 -21.9 -75.7 -141% Mar 31, 2023
Q4 2022 -24.6 -77.7 -146% Dec 31, 2022
Q3 2022 61.4 +35.7 +139% Sep 30, 2022
Q2 2022 55.7 +31.7 +132% Jun 30, 2022
Q1 2022 53.9 -2.45 -4.35% Mar 31, 2022
Q4 2021 53.1 -52.1 -49.5% Dec 31, 2021
Q3 2021 25.7 -204 -88.8% Sep 30, 2021
Q2 2021 24 -935 -97.5% Jun 30, 2021
Q1 2021 56.3 -698 -92.5% Mar 31, 2021
Q4 2020 105 -464 -81.5% Dec 31, 2020
Q3 2020 230 -73 -24.1% Sep 30, 2020
Q2 2020 959 +775 +419% Jun 30, 2020
Q1 2020 755 +644 +584% Mar 31, 2020
Q4 2019 570 +504 +767% Dec 31, 2019
Q3 2019 303 +218 +259% Sep 30, 2019
Q2 2019 185 Jun 30, 2019
Q1 2019 110 Mar 31, 2019
Q4 2018 65.7 Dec 31, 2018
Q3 2018 84.2 Sep 30, 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.